|Bid||117.55 x 1200|
|Ask||119.99 x 4000|
|Day's Range||115.35 - 120.90|
|52 Week Range||50.68 - 176.50|
|Beta (3Y Monthly)||3.62|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 23, 2018 - Oct 29, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||195.14|
NEW YORK, NY / ACCESSWIRE / November 16, 2018 / U.S. equities regained footing on Thursday as oil prices climbed and hopes of a trade agreement between the U.S. and China raised investor’s optimism. The ...
Novartis and Audentes could hold the keys to curing a pair of genetic diseases — but they will cost $4 million to $5 million apiece, an analyst predicted Monday.
Sarepta Therapeutics, Inc. (SRPT), a leader in precision genetic medicine for rare diseases, today announced that it has priced an underwritten public offering of an aggregate of 3,817,000 shares of its common stock at a price to the public of $131.00 per share. In addition, Sarepta has granted the underwriters a 30-day option to purchase up to an additional 572,550 shares of its common stock on the same terms and conditions as the initial shares sold to the underwriters. Sarepta anticipates the gross proceeds from the offering, before deducting the underwriter discounts and commissions and other offering expenses, to be approximately $500,000,000, excluding any exercise of the underwriters’ option to purchase additional shares.
Sarepta Therapeutics, Inc. (SRPT), a leader in precision genetic medicine for rare diseases, today announced that it is offering to sell, subject to market and other conditions, $500,000,000 in shares of its common stock in an underwritten public offering. Sarepta also intends to grant the underwriters a 30-day option to purchase an additional $75,000,000 in shares of its common stock offered in the public offering. Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Credit Suisse are acting as joint book-running managers of the proposed offering.
It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the end of the day, these asset management firms do not gamble the hard-earned money of the people who are on the edge of poverty. Truth […]
Investors need to pay close attention to Sarepta Therapeutics (SPRT) stock based on the movements in the options market lately.
CAMBRIDGE, Mass., Nov. 02, 2018 -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a leader in precision genetic medicine for rare diseases, today announced that management will.
Sarepta Therapeutics, Inc. (SRPT), a leader in precision genetic medicine for rare diseases, granted equity awards on October 31, 2018, that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to seventeen individuals hired by Sarepta in October 2018. The employees received, in the aggregate, options to purchase 20,960 shares of Sarepta's common stock, and in the aggregate, 10,495 restricted stock units (“RSUs”). The options have an exercise price of $133.76 per share, which is equal to the closing price of Sarepta's common stock on October 31, 2018 (the “Grant Date”).
NEW YORK, NY / ACCESSWIRE / October 31, 2018 / U.S. markets rebounded on Tuesday as trade tensions eased after President Trump hinted that the U.S. was prepared to negotiate a trade deal with China. During a Fox News interview with Laura Ingraham, President Trump said the U.S. “will make a great deal with China and it has to be great, because they’ve drained our country.” The Dow Jones Industrial Average gained 1.77 percent to close at 24,874.64, while the S&P 500 Index increased 1.57 percent to close at 2,682.63. The Nasdaq Composite Index jumped 1.58 percent to close at 7,161.65.
President & CEO of Sarepta Therapeutics Inc (NASDAQ:SRPT) Douglas S Ingram bought 16,695 shares of SRPT on 10/30/2018 at an average price of $120.39 a share.
NEW YORK, Oct. 30, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
The recovery in healthcare stocks started in May 2018 but faced some selling pressure in recent weeks as market volatility increased. The iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) fell by around 4.3% in the last week, and is down slightly on the year.
Sarepta Therapeutics (SRPT) released its third-quarter 2018 results on October 24. Its net loss per share was $1.15 in the third quarter of 2018 as compared with net loss per share of $0.78 in the third quarter of 2017.
Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of -64.71% and -0.45%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of $1.15. Losses, adjusted for non-recurring costs and stock option expense, were 56 cents per share. The results did ...
-- Third quarter 2018 EXONDYS 51® (eteplirsen) total net revenues of $78.5 million -- CAMBRIDGE, Mass., Oct. 24, 2018 -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a leader in.
Sarepta Therapeutics, Inc. (NASDAQ: SRPT ) announces its next round of earnings this Wednesday, Oct. 24. Here's Benzinga's advanced look at Sarepta's Q3 earnings report. Earnings and Revenue Sarepta's ...
Three biotech stocks are scheduled to release their third-quarter results on Oct 24. Let's take a look at how these companies are poised ahead of their earnings release.
Sarepta Therapeutics (SRPT) is expected to report its third quarter of fiscal 2018 earnings on October 24. Analysts expect revenues to increase 72.27% to $79.17 million, from $45.95 million in the third quarter of fiscal 2017. For fiscal 2018 and fiscal 2019, Sarepta Therapeutics is expected to generate revenues of $302.12 million and $429.78 million, respectively. Sarepta Therapeutics is expected to incur selling, general, and administrative expenses of $47.7 million in the third quarter of 2018 compared to $62.41 million in the third quarter of 2017, a decrease of 23.57%.